We then evaluated NCL in a subset of 47 gastric tumor sections comprehending distinct clinicopathological types (23 intestinal, 24 diffuse) as well as 7 lymph node metastases, thus reflecting a clinicopathological nature (Table 3), similar survivals as the main cohort (Figure S6), and showing SLeA expression patterns very similar to the main patient cohort. Here, NUCLEOLIN is linked to gastric neoplasm.